Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study

Gregory, Gabriel A; Robinson, Thomas I. G.; Linklater, Sarah E; Wang, Fei; Colagiuri, Stephen; Beaufort, Carine de; Donaghue, Kim C.; Magliano, Dianna J.; Maniam, Jayanthi; Orchard, Trevor J.; Raina, Priyanka; Ogle, Graham D

doi:10.1016/s2213-8587(22)00218-2

Cited by 429 publications

(340 citation statements)

References 31 publications

Supporting

Mentioning

214

Contrasting

Unclassified

Order By: Relevance

“…Besides the burden of T2DM to society, T1DM also poses heavy economic burden on patients and their families. Diabetes is estimated to affect more than 650 million people worldwide by 2040 ( 1 ). An urgent need exists for identifying biomarkers to improve the clinical diagnostic process and the therapeutic approach of diabetes ( 2 ).…”

Section: Introductionmentioning

confidence: 99%

Dissecting lncRNA-mRNA competitive regulatory network in human islet tissue exosomes of a type 1 diabetes model reveals exosome miRNA markers

Tian¹,

Xue²,

Wu³

et al. 2022

Front. Endocrinol.

View full text Add to dashboard Cite

BackgroundEmerging evidence shows that exosomes play a crucial role in the occurrence and development of diabetes and its complications. The molecules in exosomes can be regarded as important markers for the diagnosis of diseases. However, it is presently unclear the pathological association mechanism between exosomes and diabetes.ResultsIn this study, transcriptome data and lncRNA regulatory association data of human pancreatic islet-derived exosome were integrated to construct the ceRNA network. Network analysis revealed that lncRNA with differential expression were primarily involved in islet insulin secretion signaling pathways, including Hippo, TGF-beta, Wnt, FOXO, Neurotrophin and ErbB signaling pathway. Further, combined with miRNA mediated competitive regulation and differential expression analysis results, potential markers of diabetes were revealed and validated in independent datasets. Finally, we analyzed the mechanisms of diabetes based on the competitive regulatory association and function of lncRNA.ConclusionOur results suggest that lncRNA such as lncRNA PVT1, LINC00960 and hsa-miR-107 might be involved in inflammation response in T1DM, and the former lncRNA chose in the present study may serve as novel biomarkers and potential targets for the diagnosis and treatment of T1DM.

show abstract

Section: Introductionmentioning

confidence: 99%

Dissecting lncRNA-mRNA competitive regulatory network in human islet tissue exosomes of a type 1 diabetes model reveals exosome miRNA markers

Tian¹,

Xue²,

Wu³

et al. 2022

Front. Endocrinol.

View full text Add to dashboard Cite

show abstract

“…Type 1 diabetes (T1D) is an autoimmune disorder characterized by T-cell mediated insulin-producing beta cell loss leading to insulin deficiency and unregulated blood glucose levels 1 . Currently, 1.9 million individuals are living with T1D in the United States, and it affects approximately 9 million people worldwide 2 , 3 . While recent advancements in insulin therapy and the latest blood glucose monitoring technologies allow patients to measure their blood glucose levels more accurately so they may achieve optimal glycemic control, T1D associated chronic complications like ketoacidosis, heart attack, stroke, nephropathy, retinopathy, neuropathy, and hypoglycemia are still common 4 .…”

Section: Introductionmentioning

confidence: 99%

Targeted delivery of harmine to xenografted human pancreatic islets promotes robust cell proliferation

Mishra

Streeter

2022

Sci Rep

View full text Add to dashboard Cite

Type 1 diabetes (T1D) occurs as a consequence of the autoimmune destruction of insulin-producing pancreatic beta (β) cells and commonly presents with insulin deficiency and unregulated glycemic control. Despite improvements in the medical management of T1D, life-threatening complications are still common. Beta-cell replication to replace lost cells may be achieved by using small-molecule mitogenic drugs, like harmine. However, the safe and effective delivery of such drugs to beta cells remains a challenge. This work aims to deploy an antibody conjugated nanocarrier platform to achieve cell-specific delivery of candidate therapeutic and imaging agents to pancreatic endocrine cells. We approached this goal by generating core–shell type micellar nanocarriers composed of the tri-block copolymer, Pluronic®F127 (PEO100–PPO65–PEO100). We decorated these nanocarriers with a pancreatic endocrine cell-selective monoclonal antibody (HPi1), with preference for beta cells, to achieve active targeting. The PPO-based hydrophobic core allows encapsulation of various hydrophobic cargoes, whereas the PEO-based hydrophilic shell curbs the protein adhesion, hence prolonging the nanocarriers' systemic circulation time. The nancarriers were loaded with quantum dots (QDots) that allowed nanocarrier detection both in-vitro and in-vivo. In-vitro studies revealed that HPi1 conjugated nanocarriers could target endocrine cells in dispersed islet cell preparations with a high degree of specificity, with beta cells exhibiting a fluorescent quantum dot signal that was approximately five orders of magnitude greater than the signal associated with alpha cells. In vivo endocrine cell targeting studies demonstrated that the HPi1 conjugated nanocarriers could significantly accumulate at the islet xenograft site. For drug delivery studies, the nanocarriers were loaded with harmine. We demonstrated that HPi1 conjugated nanocarriers successfully targeted and delivered harmine to human endocrine cells in a human islet xenograft model. In this model, targeted harmine delivery yielded an ~ 41-fold increase in the number of BrdU positive cells in the human islet xenograft than that observed in untreated control mice. By contrast, non-targeted harmine yielded an ~ 9-fold increase in BrdU positive cells. We conclude that the nanocarrier platform enabled cell-selective targeting of xenografted human pancreatic endocrine cells and the selective delivery of the hydrophobic drug harmine to those cells. Further, the dramatic increase in proliferation with targeted harmine, a likely consequence of achieving higher local drug concentrations, supports the concept that targeted drug delivery may promote more potent biological responses when using harmine and/or other drugs than non-targeting approaches. These results suggest that this targeted drug delivery platform may apply in drug screening, beta cell regenerative therapies, and/or diagnostic imaging in patients with type 1 diabetes.

show abstract

“…An estimated 8.4 million people around the world had type 1 diabetes in 2021, and this number may rise to 17.4 million by 2040, a modelling study has predicted 1…”

mentioning

confidence: 99%

Type 1 diabetes: Global prevalence is set to double by 2040, study estimates

Mahase¹

2022

BMJ

View full text Add to dashboard Cite

Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study

Cited by 429 publications

References 31 publications

Dissecting lncRNA-mRNA competitive regulatory network in human islet tissue exosomes of a type 1 diabetes model reveals exosome miRNA markers

Dissecting lncRNA-mRNA competitive regulatory network in human islet tissue exosomes of a type 1 diabetes model reveals exosome miRNA markers

Targeted delivery of harmine to xenografted human pancreatic islets promotes robust cell proliferation

Type 1 diabetes: Global prevalence is set to double by 2040, study estimates

Contact Info

Product

Resources

About